Literature DB >> 8178926

Distinctive properties of an anaplastic Wilms' tumor and its associated epithelial cell line.

D J Hazen-Martin1, G G Re, A J Garvin, D A Sens.   

Abstract

Clinically the anaplastic variant of Wilms' tumor differs from the classical Wilms' tumor by its poor prognosis. To begin to understand and characterize the distinctive biology of this rare form of Wilms' tumor, a study of the histology, ultrastructure, and mRNA expression was performed on the anaplastic tumor and its associated cell line. The anaplastic tumor generated mouse heterotransplants that were readily used to establish epithelial cell cultures. The epithelial cultures, in turn, produced tumors when reinjected into nude mice. Microscopic evaluation revealed that the anaplastic epithelial cells were less differentiated than their epithelial counterpart in classical Wilms' tumors. In general the molecular profile of the anaplastic tumor was more consistent with that of an epithelial-rich classic Wilms' tumor than with the classic triphasic Wilms' tumor. Unlike the classic triphasic Wilms' tumor that contains blastema, stroma, and epithelial tubules, the anaplastic tumor expressed only marginal levels of insulin-like growth factor 2 (IGF-2) mRNA and imperceptible levels of the Wilms' tumor gene (WT-1), Pax-2, and Pax-8 mRNA. In common with the classic Wilms' tumor, the anaplastic variant retained the expression of the N-myc gene while failing to express C-myc. A comparison of cultures derived from an epithelial-rich, classic Wilms' tumor and the anaplastic Wilm's tumor indicated that both lacked IGF-2 and WT-1 mRNA expression. However, the well-differentiated epithelial cell culture derived from the classic Wilms' tumor expressed C-myc, Pax-8, and Pax-2 mRNA, none of which were expressed by the anaplastic epithelial cells. Furthermore, the well-differentiated epithelial cell component failed to express N-myc, which was expressed by both the primary triphasic Wilms' tumor and the anaplastic tumor. Overall, the findings indicate that patterns of gene expression within a single component do not correlate with the aggressive clinical behavior of the anaplastic Wilms' tumor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8178926      PMCID: PMC1887371     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  28 in total

1.  Epithelial differentiation in Wilms' tumor: a clinicopathologic appraisal.

Authors:  J Chatten
Journal:  Perspect Pediatr Pathol       Date:  1976

2.  Anaplastic sarcoma arising in a mature metachronous bilateral Wilms' tumor after irradiation and chemotherapy. Spontaneous versus induced malignant change.

Authors:  J E Oesterling; J C Eggleston; R D Jeffs; B G Leventhal
Journal:  Cancer       Date:  1987-06-15       Impact factor: 6.860

3.  An analysis of histology and DNA-ploidy in primary wilms tumors and their metastases and a study of the morphological effects of therapy.

Authors:  E H van Leeuwen; A Postma; J W Oosterhuis; A Meiring; C J Cornelisse; J Koudstaal; W M Molenaar
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

4.  Ultrastructure and histogenesis of the renal tumors of childhood: an overview.

Authors:  G W Mierau; J B Beckwith; D A Weeks
Journal:  Ultrastruct Pathol       Date:  1987       Impact factor: 1.094

5.  Hyperdiploidy and chromosomal rearrangements define the anaplastic variant of Wilms' tumor.

Authors:  E C Douglass; A T Look; B Webber; D Parham; J A Wilimas; A A Green; P K Roberson
Journal:  J Clin Oncol       Date:  1986-06       Impact factor: 44.544

6.  Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.

Authors:  K M Call; T Glaser; C Y Ito; A J Buckler; J Pelletier; D A Haber; E A Rose; A Kral; H Yeger; W H Lewis
Journal:  Cell       Date:  1990-02-09       Impact factor: 41.582

7.  Tissue culture of human kidney epithelial cells of proximal tubule origin.

Authors:  C J Detrisac; M A Sens; A J Garvin; S S Spicer; D A Sens
Journal:  Kidney Int       Date:  1984-02       Impact factor: 10.612

8.  Expression of insulin-like growth factor-II transcripts in Wilms' tumour.

Authors:  A E Reeve; M R Eccles; R J Wilkins; G I Bell; L J Millow
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

9.  Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues.

Authors:  J Scott; J Cowell; M E Robertson; L M Priestley; R Wadey; B Hopkins; J Pritchard; G I Bell; L B Rall; C F Graham
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

10.  Angioma-like pseudometamorphosis in Wilms' tumors subjected to preoperative radio- and chemotherapy.

Authors:  E W Becht; H J Rumpelt; D Frohneberg; P Gutjahr; W Thoenes
Journal:  Pathol Res Pract       Date:  1983-06       Impact factor: 3.250

View more
  3 in total

1.  Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition.

Authors:  Aleksandra Bielen; Gary Box; Lara Perryman; Lynn Bjerke; Sergey Popov; Yann Jamin; Alexa Jury; Melanie Valenti; Alexis de Haven Brandon; Vanessa Martins; Vincent Romanet; Sebastien Jeay; Florence I Raynaud; Francesco Hofmann; Simon P Robinson; Suzanne A Eccles; Chris Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-23       Impact factor: 11.205

2.  Is the SIOP-2001 Classification of Renal Tumors of Childhood accurate with regard to prognosis? A problem revisited.

Authors:  Jerzy Niedzielski; Katarzyna Taran; Wojciech Młynarski; Anna Sitkiewicz
Journal:  Arch Med Sci       Date:  2012-09-08       Impact factor: 3.318

Review 3.  Pediatric Tumors-Mediated Inhibitory Effect on NK Cells: The Case of Neuroblastoma and Wilms' Tumors.

Authors:  Andrea Pelosi; Piera Filomena Fiore; Sabina Di Matteo; Irene Veneziani; Ignazio Caruana; Stefan Ebert; Enrico Munari; Lorenzo Moretta; Enrico Maggi; Bruno Azzarone
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.